<DOC>
	<DOCNO>NCT00300274</DOCNO>
	<brief_summary>This trial examine impact everolimus reduce dose cyclosporine efficacy safety compare mycophenolate mofetil standard dose cyclosporine heart transplant recipient .</brief_summary>
	<brief_title>Efficacy Safety Everolimus Recipients Heart Transplants Prevent Acute Chronic Rejection</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Male female cardiac recipient 1870 year age undergoing primary heart transplantation . The graft must functional time randomization . Patients recipients multiple solid organ transplant tissue transplant previously receive organ transplant . Patients recipient ABO incompatible transplant . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>heart transplant</keyword>
	<keyword>heart disease</keyword>
	<keyword>transplantation</keyword>
	<keyword>heart IVUS assessment 12 month</keyword>
	<keyword>rate graft loss</keyword>
	<keyword>acute rejection episode</keyword>
	<keyword>survival</keyword>
</DOC>